Information Services Group Inc. (NASDAQ:III)

There are currently no videos for this stock.
To request coverage of this stock, please click the green request video box on the right.
Bands Volume 200 SMA 50 SMA 20 SMA Videos Alerts Articles Events
III Weekly Chart

Old Forum Content for III

Make a Forum Post
Become a member to view recent forum posts. Already a member? Sign in here.
Loading...
  • Wykeman: $III Nh Move continues .posted in june.
  • sierramp: @Wykeman $III Darn, I should have set an alert for the May high. That level proved to be support mid Aug. Will wait for a PB.
  • Wykeman: $III Great close yesterday. Look for 8 maybe 10. Imo
  • Wykeman: $III check out the chart. close to busting into new high territory.
  • Louis Berg: A few stocks that I see right now are $NIO, $FLGT, $GRWG, $CSIQ, $III, $BEEM, $PLL, $RIOT, $SONO
  • dagdog: $FANG - About to kick this to the curb. Doesn't seem to have momo for a Phase $III move higher (at this moment) - watching very closely. Another move down and I'm out with a small loss. Better than a big one!
  • dagdog: $FANG @ecrivain, Good advice -- patience. I'm trying. This one moves fast and I'm just at break even here. Got in as a trade for the #squeeze breakout which I should have sold when it fizzled out...now I'm "hoping" for a Phase $III move. Yesterday's low is really where support is -- I just don't know if I want to see that level of red again. Funny, you are thinking of going long. As @Dan always says, this is what makes a chart. It really "is" all about perspective, isn't it? Thanks for the shout out!
  • Tricia: $ISIS ISIS-APOCIII delivers strong trial results Final analysis of Isis Pharmaceuticals' (ISIS) antisense drug ISIS-APOCIII shows statistically significant reductions in triglycerides (64%) and apoC-III (71%) and apoC-III-associated VLDL in patients on stable doses of fibrates.Average increase of HDL-C is 52%.The 13-week Phase 2 study assessed the safety and activity of ISIS-APOCIII in 200 mg and 300 mg doses .Phase $III to commence this year.Consensus total revenue estimates for Q1 and Q2 are $36.3M and $43.7M, respectively.Consensus total revenue estimates for 2014 and 2015 are $156M and $164M, respectively.406 mutual funds have positions, up from 235 a year earlier. This started the re-look and buy backs in $TKMR, $ALNY, $ARWR etc ...
  • BuffaloBill: @Forexpro, Good afternoon, Do you use a Level $III service to watch the orderflow?
  • Forexpro: Re: Level $III, @BuffaloBill

    Hi, @BuffaloBill,

    Here's hoping that you're well, and thriving. No, level $III isn't for the likes of me. My standard setup continues to be Keltner Channels, 79-SMA and 89-EMA, and Fibs, along with stochastics that ...
  • dagdog: $QIHU - Here's what I see. The weekly came back to test the volatility breakout level and has found support around the 40 wma. This is good - maybe the start of Phase $III move higher. The daily is confirming short term support at yesterday's low. The key will be to see what it does at the 50. Once again, it all depends on when you bought & what your time frame is. The averages are flattening out so momentum may be too. If you are profitable, protect your gains. If you have a loss, don't give this much room. Keep an eye on the NDX/QQQ - they look similar. If this rolls over at the 50 consider trimming. With an $ATR of 6.6 this moves really fast. Again, all depends on where you find yourself with this position. Are we talking longer term or short term?
  • Jorma: $FB @fhsavidge - greetings! I, of late, must admit to sloppy trading of $FB as well, it had been so easy to buy low, sell high, rinse, repeat, such that I was lulled into to sleep and now am in the red with the current tranche. I will not sell my shares until again profitable, $FB will recover, the company's fundamentals will eventually out, thus my cavalier attitude. Now, as for rotation of money and where to put some to work, look at the chart of $AGU, a fertilizer stock which is just breaking out into phase $III of a vol #squeeze, should be a nice ride to at least 102. I started a position this AM, had to pay up because it has run since the open. Cheers, yes, cheers it is!
  • Tricia: BIIB: no.... $BIIB is down all on its own ... do some homework. I have compassion for your loss, BUT I am impatient with your lack of facts and obvious failure to get some ... hint pushback from FDA for $MS approval, Novartis has a $III cand for Hemphilia that met Endpoints and $BIIB is worried about ... and there is more...
  • :
  • scottto: $TTPH - Bug Stock - Tetraphase Pharmaceuticals (TTPH) has enrolled 50% of the 536 patients that it plans to recruit for the first Phase $III trial of its lead antibiotic candidate Eravacycline, which is designed to treat multidrug-resistant (MDR) infections. The study, called Ignite, is assessing the therapy for complicated intra-abdominal infections. Tetraphase has also started enrolling patients for a two-part Phase $III trial called Ignite 2 for testing Eravacycline for complicated urinary tract infections.
  • beb800: @slowtime - What???? Roman Numerals are I, II, $III, IV, $V, VI, $IX, $X, XI, $L, $C, $D, M. We do NOT use the Roman Numeral system except on things like building cornerstones, some dates on old movie credits, etc. Roman Numerals were used in ancient @Rome. Edited on Mar 20, 2014 13:00 Edited on Mar 20, 2014 13:00 Edited on Mar 20, 2014 13:07 Edited on Mar 20, 2014 13:07 Edited on Mar 20, 2014 13:13 Edited on Mar 20, 2014 13:13
  • Jorma: $CLF @fhsavidge @hwyflier - clearly, based upon your posts, you guys are high (no pun intended, "high"way flier), so I have a stock for you, ZDPY, buys land and sets up warehouses for the cultivation of cannabis, phase $III of breakout from #squeeze began today, may want to check it out, if you can see through the smoke...
  • Jorma: ZDPY @fhsavidge - alright, alright, alright, laugh if you will, I offer you a perfect phase $III breakout in a stock with rising volume, rising stochastics and RSI, and you ask if there is an ETF? Perhaps you are really the Mad Hatter, suffering the metal poisoning of mercury, rather than the @Dazed and Confused stoner lurking in the background, enticed by, what was it, @Robin's tights????
  • Iceman: ...
    It has been a relatively quiet overnight session, aside from the already noted news surrounding China's halt on virtual credit card payments sending Chinese online commerce stocks sliding, where despite an ongoing decline in the USDJPY which has se ...
  • Tricia: ...
    Here is my response ...2014-03-07: ITMN: @jnag698 - yes they did unload - but the Phase $III trial results were not known and there was doubt. On Feb 25, the stock jumped 18O% with 50M shares ... the world changed and they most likely bought shares ...
  • :
  • Edgarzb: $NWBO - NW Bio Receives Recommendation To Continue With Phase $III GBM Brain Cancer Trial Based On Data Safety Monitoring Board's Safety Review http://finance.yahoo.com/news/nw-bio-receives-recommendation-continue-130000641.html
  • Tricia: ITMN: @jnag698 - yes they did unload - but the Phase $III trial results were not known and there was doubt. On Feb 25, the stock jumped 18O% with 50M shares ... the world changed and they most likely bought shares back on the surprising news! Over 200 Funds picked up shares ...... I find it difficult to track timely inside sales ...usually I see documents 90 days after the fact .....
  • rck89: ...
    larger Phase $III studies.
  • :
  • mdonc: ITMN: They just finished their 3rd Phase $III trial. Today's $NYT had a scathing article about the FDA and how many patients with Pulmonary Fibrosis have had their life cut short by not having access to the drug. That is unless they go to Canada or the EU where it is approved. I think approval is almost a guarantee. Then the question is who will buy them or partner to commercialize the drug.
  • Tricia: CEMP: reported $AH ... Listened to call again - Ph3 Oral Trial now expecting results in Q12015, previously guided mid 2014 - not detrimental , but may move the stock down a wee bit - a chance to add or get in .... they have the submitted phase $III plan of taksta for PJI -Should here in 1H1
  • Tricia: $CEMP down 9% ... well I guess the 9 month phase $III Solitaire oral trial delay is killing them .. I will be adding because the other studies are all on track - I am still speculating that these guys are a buyout . HALO: also down 8 % .. seems the reversal has started ..... my best friend flies a 6 seater private kite and she took the CEO went to the Middle east where the CEO refused the money ..... $HALO has insulin that works ... Also Roche RHHBY will probably buy them for the Panc Ca combo ..
  • Iceman: ...
    • The capital raise and gigafactory plans are a positive says Baird's Ben Kallo, maintaining his Buy rating and $245 price target. "(1) the capital raise carries lower dilution than an equity capital raise and (2) the factory's estimated capex ...
  • Tricia: $ITMN InterMune's Pirfenidone meets Phase $III trial goals InterMune's (ITMN) Pirfenidone drug met the primary goal of a Phase $III trial by significantly reducing the progression of idiopathic pulmonary fibrosis (IPF) or mortality. "IPF is an irreversible and ultimately fatal disease characterized by progressive loss of lung function due to fibrosis (scarring) in the lungs, which hinders the ability of lungs to absorb oxygen," InterMune explains. IPF's five-year survival rate is 20-40%.Pirfenidone also met secondary endpoints with improvements in six-minute walk tests and progression-free survival.InterMune now plans to resubmit an application for FDA authorization of Pirfenidone
  • Tricia: REGN: FDA accepts Regeneron filing to widen use of Eylea The FDA has accepted Regeneron's (REGN +3.3%) application to expand the use of its Eylea therapy to treat Macular Edema Following Branch Retinal Vein Occlusion, a common vascular disease among the elderly that is caused by a blockage of one of the small veins that carry blood away from the retina.Regeneron's application follows a successful Phase $III trial.Eylea has already been authorized for other indications, including wet age-related macular edema.
  • Tricia: $BMY Bristol-Myers' Hepatitis $C combo gets breakthrough designation The FDA has granted breakthrough designation to Bristol-Myers Squibs' (BMY) Daclatasvir and Asunaprevir combination oral treatment for Hepatitis C.Specifically, the designation applies to the treatment of genotype 1b chronic hepatitis $C and is based on the results of an ongoing Phase $III trial. The FDA's decision comes after European regulators said they would give an accelerated review to Daclatasvir when used in combination with other drugs.
  • Tricia: ...
    FROM MKND: "That ADA session will be the first scientific meeting at which we will publicly present the full data from our recent Phase $III studies, MKC-171 and 175. I know some investors had wanted earlier disclosure of the complete results of tho ...
  • bxshin: ...
    Eli Lilly & Co. (LLY) said Wednesday that its ramucirumab drug reached its primary endpoint in a Phase $III study for lung cancer treatment. Shares rose 4.5% to $57.76 in recent premarket trading.

    Herbalife Ltd. (HLF) raised its outlook for the ...
  • ginny: ...
    Repros Soars on Androxal Data: Repros saw its shares soaring more than 15% on a favorable update regarding its experimental drug, Androxal, which is being developed for the treatment of secondary hypogonadism. The company met with the FDA to discuss ...
  • Matt0311: $CLDX had tried to trade phase $III of the earlier #squeeze, got stopped out today. Need to wait
  • bybyjanice: CLDX@Scotto: Aren't they suppose to have an update on Phase $III Dense Deposit Disease in FEB 2014? The fact that it is the end of the month probably also helps as a catalyst #RHRN.
  • bybyjanice: AA: Bounced yesterday, looks like phase $III from breakout of vs.
  • Esslinger: $BDSI ENDP - yesterday $AH, BioDelivery Sciences (BDSI) +27.2% $AH after the company and Endo Health Solutions (ENDP) announce a late-stage clinical trial for their new chronic pain medication showed significantly improved pain relief. The Phase $III trial successfully met its primary efficacy endpoint in demonstrating that BEMA buprenorphine resulted in significantly improved chronic pain relief compared to a placebo. $ENDP +2.4% AH. Although it's pulled back from the high of $8.75 $AH, it is currently trading at $8, still well above the close of $6.25. Congrats to any who were long. This is a new company to me, $BDSI that is, but looking at their pipeline, I will be following now and with personal interest. Anyone else familiar with $BDSI and their relationship with ENDP? http://markets.financialcontent.com/ir/?Module=MediaViewer&GUID=26236340&Ticker=BDSI http://www.bdsi.com
  • Tricia: ...
    I am so happy you got some this morning --- in 6 months you can do a happy dance ....expect BIG news going in to ASCO 14 - which is the first week of June! ( the drug names to watch are Nivolumab and Yervoy(already approved) .... Nivo has 6 Phase ...
  • greberalan: ...
    Instead, Bristol-Myers said it would continue a mid-stage study of the drugs - an experimental medicine called nivolumab and an approved melanoma treatment called Yervoy - before moving them into a larger Phase $III lung cancer trial. Both drugs enh ...
  • C.K.: $PBYI - $126.80 Second day of slight distribution off its rejected high $143.65 made yesterday. Price appears to be holding the 8-D $MA of $124.51 I actually would like to see more distribution on this thinly traded stock in order to add more to my Long holding. I think $PBYI will rise significantly if its drug in development "neratinib" proceeds in Phase $III Trial with positive results -- yes, dreaming on my part for this result
  • Tricia: BMY: @BybyJanice ... we are going to make money with this one....... even the mental midgets of #CNBC were hawking it today ...3 X's .... remember, last ASCO ...6 Phase $III Clinical trials with Nivolamamib...... plus they already have Yervoy ..... I added some back in early Dec ....
  • bfolkerts: $CSIQ - Would you consider this the completion of Phase $III on a VS breakout?
  • bfolkerts: $CSIQ - Thanks @Tim! Is there a good comprehensive video from @Dan that explains when to buy and sell from VS breakouts? I understand the phases, but am unsure if to buy on the initial breakout. Or to only purchase once it's completed phase $III, and poised to go higher?
  • chuckd: $CSIQ - @bfolkerts - as I understand it, its a matter of managing risk over time, getting the most information about a potential trade before putting your money at risk. Waiting for phase $III creates less risk for less time and provides you with more information about the possible behavior of a stock in the near term future. But, hey, its your timeframe.. Hope this helps. Cheers.
  • Esslinger: ...
    The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the $CE mark approval, utilizes the scientific principles of intra-aortic balloon counterpulsation applied ...
  • Jorma: $PCYC - trading halted on report that phase $III trial halted due to patient improvement (therefore a good thing!), congrats to all who are long.
  • MartySS: $NWBO - NW Bio's International Phase $III GBM Brain Trial Is Subject Of BBC TV Report In The UK according to pr newswire. stock is only mowing pennies though
  • BuffaloBill: ...
    What generally happens over a 2 year Phase $III study to stocks based on others that were sucessful, can the study be complete say in 6 month approval. Not an important question just curious with the past.

    The chart will let me know whats h ...
  • scottto: ...
    $OPHT raised money in their IPO to fund the Phase $III Trial. They now appear to have plenty of money on hand to complete the trial.

    (Phase $III Trial Info start)

    A Phase 3 Randomized, Double-masked, Controlled Trial to Establish the Safety a ...
  • scottto: ...
    The Phase $III trials may have a hiccup. Safety, efficacy, you name it. FDA could ask for more data and prolong things. Also, the company being pretty small could suffer some financial set back. It's size also makes it a takeover candidate. The whol ...
  • BuffaloBill: ...
    That magical yellow rock. It started a movement west, it has been the reason for war. It also has no real use other than its aesthetic appeal. In terms of the markets it is seen as a store of wealth in crisis and a proxy for inflation, but most of t ...
  • bybyjanice: CBST: Up today after reporting positive stage $III news about gram negative antibiotic treatment (ceftolozane/tazobactam) for intra-abdominal infections. http://www.cubist.com/news/117-cubist_announces_positive_top-line_results_from_phase_3_trial_of_ceftolozane_tazobactam_in_intra-abdominal_infections
  • Edgarzb: $NWBO - 8:19 am Northwest Biotherapeutics announced that the number of events required to trigger the first interim analysis of its Phase $III clinical trial in patients with Glioblastoma multiforme brain cancer has been reached (NWBO) : Co announced ...
  • Tricia: CELG: Two Studies Highlight Retrospective Analyses of Phase $III Study of POMALYST# .. http://boardvote.com/sym/CELG/500557
  • Tricia: ...
    These process improvements are intended to increase quality, consistency, efficiency, and cost-effectiveness, and support ImmunoCellular's vaccine manufacturing requirements for conducting potential phase $III registration trials and for commercial ...
  • :
  • Jorma: $MDXG - vol #squeeze expansion phase I had 3 up days, phase II appears to have lasted one day (yesterday), now phase $III potentially beginning today, up 2 % to 6.9 (7.03 intra-day high) after report that FDA has agreed with some minor tweaks based on the previously reported "untitled letter," the company is clearly happy with the outcome, now can go forward unobstructed with $CMS reimbursement schemata already established, and which is extremely favorable for MiMedx relative to competitors such as Shire, Osiris, etc. http://scharts.co/1eTujyC
  • Jorma: $MDXG @lerner101 - I think 7 has been, and will be, resistance, but I expect if that happens, a phase II down to 6.25-6.50 will occur, and then we have to see if Phase $III can take us past 7 and into bluer skies!
  • lerner101: $MDXG @ Jorma Okay, good point. Will watch to add if we get that phase $III, if we don't get there and it just goes up, well that would be A-OK.
  • bybyjanice: CRME@Jorma@Esslinger: Here is some history on this drug. I don't know why the FDA halted phase $III clinical trial. I too have been concerned about the downtrend of the stock (SSH). It appears to be heading straight for the 200dma. http://www.cardiome.com/pipeline/atrial-fibrillation/vernakalant-iv http://www.biomedreports.com/20121218116850/cardiome-shares-remain-low-on-mercks-abandonment.html
  • Tricia: ...
    If Galena Biopharma can successfully capture just 5 percent of this market, that would mean annual Abstral sales of approximately $185 million. Sales took off and will provide cash flow for final Phase $III studies ...very impressive that they got ...
  • Tricia: GILD: Hepatits $C news: Phase II trial . here is the SINGLE TABLET all oral regime sofosbuvir and ledipasvir (no interferon) achieved nearly 100% sustained virologic response SVR in both treatment-naive and treatment-experienced patients. Incredible ... http://hepatitiscresearchandnewsupdates.... Genotype 1accounts for nearly 70% of Hepatitis $C .... This is Phase $III but you can understand why $GILD is saying it will be available by YE 2014 and may be sooner with FDA tell me gain why you are not holding GILEAD? $ABBV is claiming their P3 candidate has 96% cure .. mot sure of ADCOMM date ... but we need to follow this ..
  • Poppy: ...
    1. Will the FDA approve CLL label ahead of Phase $III data?
    2. Could the FDA then have additional data requests leading to a potential delay?
    3. Will there be an ODAC panel?
    Here's what I concluded: the FDA is likely to approve independent of Pha ...
  • Edgarzb: $NWBO - My understanding is that the phase $III GBM study is for operable GBM patients which uses DC vaxL. The DC VAX Direct is for inoperable tumors.
  • slowtime: ...
    "We are encouraged by the initial safety and activity profile observed to date and believe CDX-1127 could play an important role in the field of cancer immunotherapy," said Howard A. "Skip" Burris, $III, $MD, Chief Medical Officer and Executive Dire ...
  • captron: LINE - Phase $III is looking a little weak this morning. Moving my stop up.
  • dagdog: MARKETS @otnancy - I hate when that happens! Make you feel like you're on a roller coaster ... right at the top...just before the big plunge down. Don't know why this happened but looking at the intra day charts kinda helps it to make some sense. Many charts jumped higher out of squeezes and are now pulling back to test the breakout levels. Hopefully to find some support around these levels to begin Phase $III as @Dan talks about. Causing some concern is that the NDX didn't find support at the breakout level and is now testing it as resistance. Only time will tell.
  • SADL: $RY - @DAN, Thanks for covering $RY (RY.TO) on the weekend. I am long in its Canadian equivalent as well as in National Bank of Canada NA.TO, waiting for pull backs to add to my positions. The 6 major Canadian banks are all doing great for 2 reasons: (1) they have gone through the financial crisis quite well and (2) their capital base already exceeds Basel $III requirements. Should the overall Canadian start moving, especially with signs of movement in the energy and mining (48% of the value of the TSX), the banks might be forming new high bases. if some SMM members invest in the Canadian market and are looking at banks, I might suggest the $ETF - XFN.TO as a good move, once it pulls back.
  • Tricia: ...
    2) $PII - CDX- 1135 Dense Deposit Disease - ( kidney) Phase II trial started this summer - preliminary results are due by year end ..... $IF THE RESULTS are good, the ORPAHN drug status Accelerated Approval (ODS,AA) will take over and bring this ...
  • Tricia: ...
    2) $PII - CDX- 1135 Dense Deposit Disease - ( kidney) Phase II trial started this summer - preliminary results are due by year end ..... $IF THE RESULTS are good, the ORPAHN drug status Accelerated Approval (ODS,AA) will take over and bring this ...
  • Tricia: ...
    2) $PII - CDX- 1135 Dense Deposit Disease - ( kidney) Phase II trial started this summer - preliminary results are due by year end ..... $IF THE RESULTS are good, the ORPAHN drug status Accelerated Approval (ODS,AA) will take over and bring this ...
  • Tricia: $REGN : Reegeneron, Sanofi drug slashes "bad" cholesterol almost in half A drug developed by Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) cut levels of the "bad" $LDL cholesterol by 47% in a Phase $III trial of 103 patients. No major side effects were experienced. The treatment, called Alirocumab, is part of a new class of injectable cholesterol medicines that block a protein called PCSK9. Amgen (AMGN) and Pfizer (PFE) are among those developing such drugs, which could each generate sales of $3B or more. Regeneron and Sanofi hope to file for authorization of Alirocumab by late 2015 after the results of another 11 studies are released
  • Tricia: ...
    $IF this combo gets through Phase $III ( signs are good so far) ... the market for Vertex changes dramatically ... they would be able to treat 50% of the $CF population .... 50,000 PTs x$300,000K = 1.5B not a bad return ..

    I added to my p ...
  • Tricia: ...
    Be aware .... the Blood cancer space is no longer an empty room ..... Gilead has a new candidate, Roche has Phase $III studies that will be presented either at of just before the Upcoming $ASH conference in New Orleans ......

    I remain long, b ...
  • Esslinger: $CTIC - (+10.3%) Reaches deal with the FDA for a Special Protocol Assessment for its Phase $III testing for its pacritinib drug candidate for patients with myelofibrosis. Actually as I type this, 22%! Day 1 of a break out?
  • tnt: $PTLA, I mentioned in the forum Monday, under the radar biotech working on some very big things. You all have heard of or seen commercials for the new blood thinners like Xarelto. These drugs are replacing traditional blood thinners like heparin/lovenox which require injections. One problem, there is no good reversal agent in case someone develops life threatening bleeding. Portola has the most advanced reversal agent in testing right now. It binds factor Xa drugs like Xarelto. Also, Portola is working on the their own Factor Xa blood thinner with phase $III study looking for first indication in Acute Medically Ill VTE Prevention. This would be first in class to get this indication. I am an investor in Portola & will add shares on dips. Do your on due diligence
  • Tricia: IMMU: hope for Lupus .... now up 100% YTD Epratuzumab is a humanized anti-CD22 antibody with potential uses in the treatment of lymphomas and autoimmune disorders such as lupus http://seekingalpha.com/article/1720532-immunomedics-inc-poorly-understood-biopharma-with-asymmetric-risk-reward?source=feed_f http://clinicaltrials.gov/show/NCT01510561 - phase $III to start soon ....
  • captron: $III - Great little stock for someone looking for an inexpensive uptrending stock. It won't make you rich over night but you shouldn't loose either. It's cheap so you can own a lot. Several encouraging articles along with strong buy ratings have been keeping it on a steady uptrend for a couple months. It does not offer many good buying opportunities. I had been waiting to add and finally got the chance Friday. Earning are not until November and the company has a history of beating the estimates. Here is one of the stories. Have a great weekend. http://finance.yahoo.com/news/information-services-group-upped-strong-132002133.html
  • Tricia: $SSH @bybyjanice .... perhaps I was not clear ..... the medical device tax was not well thought out .... my point was that it's impact is not going ot be felt in $SSH ... it is several years away from final approval .... You just reminded me of another benefit ....... currently the readmission rate for Grade $III CHF is very high .... ( insurers are downright nasty about that second admission and blame the hospitals for poor outcomes due to lack of care .... $SSH CPulse will dramatically reduce those readmissions ..... those Hospital CEO's might be willing to pay the 3% tax ... versus losing the reimbursed readmisssion !
  • pcotton: $SSH - @Tricia - Interesting (but sad) so many people have stage $III CHF. Have you been able to come across any similar figures for unstable angina, which is usually managed fine with either stents or medications. There are some patients who are not candidates for stents, or even open bypass graft, but I haven't been able to find how prevalent that is. From ceo Rosa's presentation, I didn't gather that he was enthusiastic about the product's applicability, but maybe he thought that would be premature.
  • Tricia: SRPT: I believe the stock will rise on this news ... it did and now it faded .... I believe it will go up due to GSK's/ Prosena failure ... the naysayers regarding Sarapeta's candidate are still there.... if you believe that erlirpsten will get the coveted $AA, then you buy .... if not sure then wait.... I believe it will ... but that is on MY prayers for enlightenment of the FDA...... not fact ... BAIRD has quite a bit to say ,,,, but they were short this most likely ...... credibility is everything and some of these analysts are simply not credible... $GSK, Prosensa drug for Duchenne Muscular Dystrophy fails Phase $III GlaxoSmithKline's (GSK) and Prosensa's (RNA) Drisapersen treatment for Duchenne Muscular Dystrophy fails to reach its primary goal in a Phase $III trial of enabling a statistically significant improvement in the Six-Minute Walking Distance test vs a placebo.
  • Tricia: NWBO: Clarification...... Northwest biotherapuetics received permission to BEGIN Phase $III trial in Germany for GMB - Glioblastoma...
  • Tricia: ...
    Co announces the first patient implant in the Co's US pivotal trial, COUNTER HF. The COUNTER HF study is a prospective, randomized, multi-center, controlled trial that will evaluate the safety and efficacy of the C-Pulse system for the treatment of ...
  • nasada: FB...looks like phase $III of a vs on the 1 hour chart since the first of the month...picking up some Dec $40 calls
  • Tricia: ...
    Every day there is news about a Phase I , II, or $III study .... about the FDA and the EMA, about trial completions in Japan, Australia, Canada ... etc.....

    A new drug candidate will require thousand of patients and billions of data points with ...
  • Tricia: ...
    Sunshine Heart, Inc., an early-stage medical device company, focuses on developing, manufacturing, and commercializing C-Pulse Heart Assist System for treatment of Class $III and ambulatory Class IV heart failure.
    The C-Pulse Heart Assist System u ...
  • Iceman: $MACK - Paper on Merrimack's Phase II trial of MM-398 drug published - The British Journal of Cancer has published a paper about the Phase II trial of Merrimack Pharmaceuticals' (MACK +5.2%) MM-398 drug for treating late-stage pancreatic cancer. The study met its primary endpoint, with 75% of patients surviving at least 3 months, including 25% who reached the one-year mark. The median overall survival was 5.2 months, while 50% of patients showed evidence of disease control. MM-398 is now in Phase $III trials. (PR) Last week, $SA author Ross Breckendridge noted that Merrimack's share price has been swinging significantly recently in response to interim clinical trial data from MM-121. Breckendridge believes that any downside "has been due to the misconception of the meaning of the data released, and a somewhat poor communication effort by the company."
  • Iceman: $GTXI - GTx's Enobosarm fails in two late-stage trials GTx's (GTXI) Enobosarm drug for non-small cell lung cancer failed to meet its primary endpoints regarding lean body mass (LBM) and physical function in two Phase $III studies. However, Enobosarm did demonstrate "significant quantitative advantage in LBM compared to placebos in both trials." GTx intends to hold talks with the FDA and EU regulators about the company's next steps.
  • DAN: $MRVL -- starting Phase $III of the July volatility #squeeze.
  • Tricia: NWBO: Speculative speculative stock period ...read the 40 comments in this article and then let me know your thesis http://seekingalpha.com/article/1561452-a-small-biotech-with-breakthrough-potential-in-cancer-treatment?source=kizur They have just started to enroll Phase $III (and it was a why not try it thing ) ( and financially they are in serious trouble) .. Fro me this is a stong NO, NO, NO ... but I hope I am wrong ...
  • Tricia: $SSH - here is company to research ... and maybe buy! Sunshine Heart jumps on an upbeat report from Runway Research Sunshine Heart (SSH +17%) pops on a report out of Runway Research saying the company's C-Pulse Heart Assist System is a "game changing device" that could lead to a buyout worth as much as $50 per share. $SSH received unconditional FDA approval for the C-Pulse(R) system's U.S. pivotal trial in November, 2012. With the device, Runway says that $SSH is targeting the New York Heart Association's Class $III and ambulatory Class IV Congestive Heart Failure market, which is an enormous untapped opportunity with approximately 1.5M patients in the U.S. and another 3.7M patients in Europe. If the company penetrates just 10% of this market, the firm says the opportunity could reach over $5B. ( HMM ...verdy iteresting and Not stuupid) lol
  • JeffTx1957: ...
    I'm not optimistic about Vical(VICL_) or its skin cancer immunotherapy Allovectin. I believe failure will be the most likely outcome of the phase $III study when results are announced in the third quarter.

    Before I explain the fundamental bear t ...
  • Tricia: ...
    Unlike many big pharma's, these guy were smart to protect their RITUXIN market ( everyone gets rituxin..) and this week they announced more positive Phase $III data for GA101 (obinutuzumab). The final part of the CLL11 trial, which demonstrated th ...
  • Tricia: SRPT: NDA Accepted without Phase $III is a very big deal .... very good news - so happy for these families!
  • Tricia: RHHBY: more good news for Roche ..... WATCH BIIB ..... and $HALO .... earning s tomorrow - http://www.roche.com/investors/ir_agenda/halfyear-2012.htm, http://www.fiercebiotech.com/story/roche-highlights-more-upbeat-phiii-data-breakthrough-leukemia-contender/2013-07-24 Roche's obinutuzumab (GA101) delayed disease progression longer than MabThera/Rituxan in people with one of the most common forms of blood cancer Phase $III CLL11 study showed GA101 plus chlorambucil, a chemotherapy, was superior to MabThera/Rituxan plus chlorambucil in helping people with previously untreated chronic lymphocytic leukemia live longer without their disease worsening Final data from the CLL11 study will be submitted to the American Society of Hematology's 55th Annual Meeting in December 2013
  • Tricia: ...
    GTx I has PIII study due on Enobosarm for the Prevention and Treatment of Muscle Wasting in Cancer Patients - the stock soared on $PII results but on July 10th it dropped 25 % due to A F's article....

    July 11, 9:25 AM More on Wedbush's GTx (G ...
  • Iceman: ...
    ?Tier 1 common ratio 9.44%**, down 26 bps sequentially, largely due to repurchases of ~$539 million in common shares announced during the quarter (Basel $III pro forma estimate of ~9.10%)
    ?Tier 1 capital ratio 11.07%, Total capital ratio 14.35%, L ...
  • Tricia: ...
    July 11, $CELG says a Revlimid/ dexamethasone combo met its primary $PFS endpoint in a Phase $III study of newly diagnosed multiple myeloma patients. Shares +8%. # $GOOD NEWS! , 3 analysts expect favorable detailed data at ASH.

    July 2, Co annou ...
Visit the Trading Forum to join in the discussion.
Stock Price $5.27
Change -0.38%
Volume 100,116

Information Services Group, Inc. is engaged in the assessment, evaluation, negotiation and management of service contracts related to outsourcing, insourcing, offshoring, and shared services.

Request Video of III
Already a member? Sign in here.
Past Month

Leading Peers

Past Month

Lagging Peers

Dan Fitzpatrick

Stock Market Mentor gives you EVERYTHING you need to succeed in the market; all in one place. How easy is that? Dan Fitzpatrick and his elite community of traders share trading ideas, strategies and much more. Dan Fitzpatrick--a world class Technical Analyst, trading coach and regular CNBC contributor--gives you access to all of this with a 30 day trial membership for just $7.77. Get started TODAY and start trading better TOMORROW with the following premium content:

  • Nightly video Strategy Sessions with a game plan for tomorrow
  • Got a stock you want Dan to look at? Just ask.
  • Patent pending video alerts instantly delivered to you when one of Dan’s trading signals is triggered. This is not your typical price alert. This is a short video explaining the action you need to take to make money. No more “Woulda, coulda, shoulda”
  • Access to over 90,400 stock analysis videos
  • Access an ever expanding library (90,400) of educational videos that will save you time and make you money

Join a team of friends and traders that have one thing in common; a burning desire to succeed.

Become a Member Today!

Gain immediate access to all our exclusive articles, features, how-to's, discussion group and much more...

Satisfaction Guaranteed!

Your Stock Market Mentor membership comes with a 30 day, no questions asked, 100% money back guarantee!